Drug shortages raising supply chain risk, says FDA Securing Pharma ... including unapproved versions of AstraZeneca's breast cancer drug Faslodex (fulvestrant), Amgen's white blood cell stimulator Neupogen (filgrastim), and Roche's cancer drugs Rituxan (rituximab) and Herception (trastuzumab). ... |
